Stomach Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with stomach cancer or cancer where the stomach meets the food pipe (oesophagus), confirmed by a tissue biopsy, and your cancer may be removable by surgery
- You are currently being treated with standard chemotherapy drugs (such as 5-Fluorouracil or Capecitabine, combined with Oxaliplatin, with or without Docetaxel)
- You are male or female and are over 18 years old
- You are willing and able to sign a consent form agreeing to take part in the study
- For the lookback part of the study (retrospective cohort): tissue samples and medical records from your previous treatment are available for review
Who may not be able to join:
- You are under 18 years old
- Your stomach cancer is at a very early stage, or is at stage T2 with no spread to nearby lymph nodes
- You have a type of stomach cancer called linitis plastica (where the stomach wall becomes stiff and thickened)
- Cancer cells have been found in the fluid around your abdominal organs, or the cancer has spread to the lining of your abdomen
- Your cancer has spread to distant parts of your body (distant metastases)
- You do not wish to take part in the study
- You do not agree to allow your tissue samples to be used for research
- You stopped your treatment early due to other health conditions or not being able to follow medical advice
- You have a health condition that makes taking biological samples (such as blood or tissue) either unsafe or not useful for research (confirm with trial site)
- You have a mental health condition that affects your ability to accurately complete questionnaires or follow medical guidance
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Genomic alterations in tumoral tissue in responders and non-responders; Quantitative and qualitative analysis of the tumor microenvironment composition in responders and non-responders; Analysis of cell-free DNA (cfDNA) from blood samples in responders and non-responders; Analysis of circulating tumor cells (CTC) from blood samples in responders and non-responders.; Peripheral blood mononuclear cells (PBMCs) and host immunity parameters in responders and non-responders
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.